Citi analyst Samantha Semenkow initiated coverage of Larimar Therapeutics with a Neutral rating and $4 price target. The clinical-stage biotech is focused on developing CTI-1601 for the treatment of rare neuromuscular disorder Friedreich’s Ataxia, or FA, Semenkow tells investors. While news of the FDA having recently removed a full clinical hold on CTI-1601 is "a positive for Larimar," she continues to have questions surrounding the ability to identify a dose that is both safe and efficacious, keeping her on the sidelines.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LRMR:
- Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference
- Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
- Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day
- Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601
- Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research
